Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease, Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/18/2019 |
| Start Date: | August 2003 |
| End Date: | August 2006 |
A Phase 2, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Televancin (TD-6424) for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety
administered to patients with bloodstream infections and whether telavancin is effective in
treating these infections.
administered to patients with bloodstream infections and whether telavancin is effective in
treating these infections.
Inclusion Criteria
- Documented S. aureus bacteremia
Exclusion Criteria
- Patients who had received or would have received more than 72 hours of potentially
effective systemic antistaphylococcal therapy within 7 days prior to randomization. The
following agents were considered potentially effective antistaphylococcal therapy:
antistaphylococcal penicillins (including nafcillin, oxacillin, or cloxacillin),
cephalosporins, fluoroquinolones, glycopeptides (including vancomycin and teicoplanin) and
linezolid
We found this trial at
1
site
Click here to add this to my saved trials
